Fast-Tracked to the Medicine Cabinet — President Trump's Executive Order Accelerates Psychedelic Therapies

On April 18, 2026, President Trump signed an Executive Order titled "Accelerating Medical Treatments for Serious Mental Illness," directing multiple federal agencies to accelerate research into, and access to, psychedelic drugs for the treatment of serious mental health conditions. The Executive Order represents a significant policy shift and carries meaningful implications for manufacturers of psychedelic therapies, companies operating in the broader innovative therapeutics space, and healthcare providers and patients relying upon these treatments in practice.

Background and Rationale

The Executive Order is framed around the crisis of serious mental illness in the United States. As stated in the order, individuals suffering from major depressive disorder, substance use disorder, and other serious mental illnesses frequently relapse or fail to respond to standard medical and psychiatric therapies. Notwithstanding the potentially harmful effects of psychedelic drugs used recreationally, evidence that certain psychedelics can address treatment-resistant depression and other types of mental illness has existed for decades. Despite substantial federal investment in mental health research, the Administration found that approved therapies have yet to produce "enduring improvements" for the most complex patients.

Veterans are singled out as a population of particular concern. The order notes that veteran suicides have exceeded 6,000 per year for over two decades, and the current veteran suicide rate is more than twice that of the non-veteran adult population. President Trump emphasized the "life-changing potential" of psychedelic treatments for veterans during the signing ceremony.

The political backdrop is also noteworthy. Reporting indicates the Executive Order was prompted in significant part by outreach from podcaster Joe Rogan, who texted the President information about ibogaine research and the opioid crisis. The order was reportedly drafted in less than a week, and the Administration secured "uniform support" from HHS Secretary Robert F. Kennedy Jr., FDA Commissioner Marty Makary, CMS Administrator Mehmet Oz, and NIH Director Jay Bhattacharya.

Products Covered

The Executive Order applies broadly to "psychedelic drugs," with ibogaine compounds specifically named. While the order does not enumerate every substance, the class includes drugs that have received FDA Breakthrough Therapy designations. FDA Commissioner Makary announced at the signing ceremony that investigational new drug (IND) clearance had been granted for ibogaine, meaning U.S. clinical trials can now begin for that substance. The Commissioner also stated that three new drug applications are "imminent" and that Commissioner's National Priority Vouchers would be issued to three psychedelic candidates the following week.

Key Provisions of the Executive Order

The order directs several key agency actions, including:

• Directs the FDA Commissioner to "provide Commissioner's National Priority Vouchers to appropriate psychedelic drugs that have received a Breakthrough Therapy designation and are in accordance with the criteria of the National Priority Voucher Program. ”The CNPV program, launched in June 2025, is designed to reduce FDA's NDA review timeline from the standard 10 to 12 months to a target of just one to two months through a collaborative "tumor board-style" review process and enhanced presubmission engagement. The program has already yielded several approvals in record time.
• Directs FDA and the Drug Enforcement Administration (DEA) to "facilitate and establish a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds, under the Right to Try Act" (21 U.S.C. § 360bbb-0a).
• Directs the Secretary of HHS, through the Advanced Research Projects Agency for Health (ARPA-H), to allocate at least $50 million from existing funds to support and partner with state governments that have enacted or are developing programs to advance psychedelic drugs for serious mental illnesses. This funding is expected to benefit Texas's ibogaine research program most immediately.
• Directs HHS, FDA, and the Department of Veterans Affairs (VA) to collaborate with each other and with the private sector to increase clinical trial participation, data sharing, and real-world evidence generation regarding psychedelic drugs, with priority given to drugs that have received Breakthrough Therapy designation. The agencies are directed to sign data-sharing memoranda to ensure that clinical study data from across the executive branch is made available to the FDA to facilitate timely drug evaluation and approval. Approximately 30 psychedelic studies are reportedly underway at VA sites, the majority of which are clinical trials covering conditions such as co-occurring PTSD and alcohol use disorder, depression in spinal cord injury, and implementation-focused studies.
• Instructs the Attorney General, in consultation with HHS, to initiate and complete review of any product containing a Schedule I substance that has successfully completed Phase 3 clinical trials for a serious mental health disorder, so that rescheduling may proceed "as quickly as practicable" for products ultimately approved under Section 505 of the Federal Food, Drug, and Cosmetic Act. By initiating the rescheduling review after Phase 3 completion but prior to an FDA approvability decision, the order could in theory shave off up to three months of post-approval delay in the rescheduling process. However, commentators have questioned the practical impact, noting that the DEA is already required by statute to reschedule drugs within 90 days of FDA approval.

Takeaways and Broader Implications for Innovative Therapies

While the Executive Order is focused on psychedelic drugs, its structural elements carry broader significance for manufacturers of other innovative therapies and other industry stakeholders:

The CNPV program is expanding as a pathway for breakthrough therapies generally. The CNPV program's five priority areas — public health crisis response, innovative breakthrough therapies, large unmet medical needs, onshoring and supply chain resilience, and affordability — extend well beyond psychedelics. Regenerative medicine companies, gene therapy developers, and other manufacturers with Breakthrough Therapy or Regenerative Medicine Advanced Therapy (RMAT) designations should evaluate whether their products align with the CNPV criteria. The program accepts NDAs, biologics license applications (BLAs), and manufacturing or efficacy supplements.

The Administration's willingness to use executive authority to accelerate specific therapeutic classes is a precedent. The Executive Order follows a December 2025 executive order on medical marijuana and cannabidiol research, suggesting a pattern of using presidential directives to advance categories of investigational therapies that face regulatory or scheduling obstacles. Manufacturers of therapies in other novel categories should anticipate that similar executive attention could be directed toward their therapeutic areas where they make the case that such is warranted.

Interagency data sharing and real-world evidence frameworks could benefit other fields. The order's directive to create data-sharing memoranda between HHS, FDA, and VA, and to leverage real-world evidence, reflects a broader trend toward integrating non-traditional evidence into the regulatory approval process. Regenerative medicine manufacturers, who frequently face challenges generating large clinical trial datasets for rare or complex conditions, may benefit from similar frameworks being extended to their products.

We don’t know if this change will impact ketamine or other specific psychedelic drugs. Advocates for psychedelics will hope that this initiative yields wider approval for popular clinical use-cases, such as ketamine therapy for treatment-resistant mental illness. However, the Executive Order does not commit to evaluating any specific therapies except ibogaine. FDA issued a warning to healthcare providers and patients regarding potential risks associated with compounded ketamine in October 2023, so it is worth watching how communications that follow this Executive Order interact with that past guidance.

For healthcare providers and patients, input from professional boards remains important. Medical and other state professional boards are independent of FDA.  Providers in particular should monitor any professional board guidance regarding appropriate utilization of psychedelic medications in clinical practice to avoid discipline. 

Political dynamics remain a wild card. The Executive Order's origins in political relationships — rather than in a formal policy review process — underscore the degree to which regulatory pathways for novel therapies are subject to political influence in the current environment. Companies in the innovative therapies space should maintain robust government affairs capabilities and be prepared for both acceleration and abrupt course changes in regulatory policy.

Conclusion

The Executive Order on psychedelics is a landmark policy development that signals strong Administration support for an accelerated pathway for psychedelic-assisted therapies. However, the order is not self-executing: its effectiveness will depend on FDA, DEA, and HHS follow-through, the outcome of NDA submissions currently in the pipeline, and the resolution of significant implementation questions around Right to Try and other issues. Manufacturers of psychedelic therapies and other innovative products should engage proactively with the relevant agencies and monitor developments closely. We will continue to track implementation of this Executive Order and provide further guidance as events unfold.

Visit our FDA & Healthcare Regulatory Resource Center for the latest regulatory updates and practical insights across life sciences, healthcare and healthtech.